oral.bpc 157 bpc bioavailability oral bpc-157 vs injection effectiveness The hype around a new class of injectable drugs oral bpc 157 peptide sciences Enhanced Oral Bpc 157 Capsules,

Research using two demyelination animal models, including experimental autoimmune encephalomyelitis (EAE), which is the standard animal model for MS, demonstrated that thymosin beta-4 promoted OPC differentiation and supported remyelination

This is highly speculative because: Oral bioavailability differs between species Route of administration affects systemic exposure Species differences in peptide metabolism and clearance are unknown Current Practice Patterns Current practice patterns from unregulated sources typically involve: Subcutaneous injection: 0.25-0.5 mg once or twice daily, administered near injection sites for localized effects or abdominally for systemic distribution

Light-headedness shortly after administration

Is this product intended for human use